Biotech News
GSK announces charges for legal matters
GSK today announced that it will record a legal charge in the fourth quarter of 2008 of $400 million elating to an ongoing investigation.
Open original release
Related news
GSKGSK plc2026-06-25 13:46 EST
GSK announces commencement of tender offer to acquire Nuvalent, Inc.
GSKGSK plc2026-06-25 13:46 EST
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
GSKGSK plc2026-06-25 13:46 EST
GSK’s momelotinib granted Orphan Drug Designations in the US and EU for VEXAS syndrome
GSKGSK plc2026-06-25 13:46 EST
GSK enters agreement to acquire Nuvalent, Inc.
GSKGSK plc2026-06-25 13:46 EST
Bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
GSKGSK plc2026-06-25 13:46 EST
GSK to showcase long-term outcomes and pipeline expansion with latest oncology research at ASCO and EHA
GSKGSK plc2026-06-25 13:46 EST
GSK’s RSV vaccine, Arexvy, receives expanded approval in Japan for adults aged 18–59 at increased risk
GSKGSK plc2026-06-25 13:46 EST
GSK enters exclusive collaboration with SBP Group, a market leader in hepatology in China, to accelerate bepirovirsen at launch
GSKGSK plc2026-06-25 13:46 EST
GSK and Xenoport resubmit new drug application for Solzira™ in restless legs syndrome
GSKGSK plc2026-06-25 13:46 EST
GlaxoSmithKline receives European Commission approval to market alli® (orlistat 60mg)
GSK plc
GSK plc is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Recent company news
GSKGSK plc2026-06-26 06:01 EST
GSK announces commencement of tender offer to acquire Nuvalent, Inc.
GSKGSK plc2026-06-26 06:01 EST
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
GSKGSK plc2026-06-26 06:01 EST
GSK’s momelotinib granted Orphan Drug Designations in the US and EU for VEXAS syndrome
GSKGSK plc2026-06-26 06:01 EST
GSK enters agreement to acquire Nuvalent, Inc.
GSKGSK plc2026-06-26 06:01 EST
Bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
Stock data
- Close
- —
- Market cap
- —
- Exchange
- NYSE
- Sector
- Biotechnology
- Location
- United States